News | January 05, 2022
Bharat Biotech's intranasal vaccine Phase 3 trials gets approval
It has also been granted permission to conduct trials for booster dose
It has also been granted permission to conduct trials for booster dose
The test kit is compatible with all standard Real-Time PCR machines with a test run time of 85 minutes. The result turnaround time, including sample collection and RNA extraction, is 130 minutes
The virtual world makes it possible to visualize, test, understand and predict what cannot be seen, before a patient is treated
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
The first pilot study from India analyzing Covaxin-Covishield mixed doses
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Partnering to build biosynthesis processes and a pharmaceutical production platform
The Health ID will allow users to connect with different healthcare providers and enable a consent-based sharing of personal health records
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
Celltrion plans to provide dual treatment options for COVID-19; Regkirona for hospitalised patients and a nebulised cocktail therapy (CT-P63 in combination with Regkirona) for at- home settings
Subscribe To Our Newsletter & Stay Updated
